|
M.B. Antsiferov
THE USE OF INSULIN GLARGINE 300 IU/ML (TOUJEO SOLOSTAR®) IN REAL CLINICAL PRACTICE
|
№16 / 2017
|
|
E.Yu. Komelyagina, M.B. Antsiferov
DIABETIC DISTAL POLYNEUROPATHY: THE PRINCIPLES OF DIAGNOSTICS AND THERAPY
|
№16 / 2017
|
|
E.V. Biryukova
FIXED-DOSE COMBINATIONS IN THE THERAPY OF TYPE 2 DIABETES MELLITUS: THE WAY TO ACHIEVING GOOD GLYCEMIC CONTROL
|
№16 / 2017
|
|
M.E. Statsenko, S.V. Turkina, I.A. Tyshchenko, S.V. Fabritskaya, L.V. Poletaeva
POTENTIALS FOR THE DRUG CORRECTION OF SECONDARY MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE AND COMORBID PATHOLOGY
|
№6 / 2017
|
|
N.A. Shevkunova
THE USE OF ANTIBACTERIAL DRUGS DURING ORTHOPAEDIC ALIGNMENT WITH REMOVABLE LAMINAR DENTURES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TAKING INTO ACCOUNT THE RESULTS OF PCR-BASED DIAGNOSTICS
|
№6 / 2017
|
|
N.A. Chernikova
CURRENT POSSIBILITIES OF COMBINED THERAPY IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS
|
№5 / 2017
|
|
A.S. Ametov
PATHOPHYSIOLOGICAL APPROACH AS A BASIS FOR THE SELECTION OF STRATEGY FOR THE SUCCESS TREATMENT OF TYPE 2 DIABETES MELLITUS
|
№5 / 2017
|
|
A.M. Mkrtumyan (1), S.V. Podachina (1), M.I. Sviridova (2)
EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ON CARDIOVASCULAR RISK MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№16 / 2016
|
|
M.B. Antsiferov (1), V.V. Fadeev (2), T.B. Morgunova (2)
MODERN APPROACHES TO THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№16 / 2016
|
|
M.B. Antsiferov (1), G. Schernthaner (2)
CURRENT APPROACHES TO THERAPY OF TYPE 2 DIABETES MELLITUS IN THE ERA OF NEW DATA ON CARDIOVASCULAR SAFETY
|
№16 / 2016
|
|
O.M. Koteshkova, L.P. Molina
EFFICIENCY OF MULTICOMPONENT THERAPY IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (CLINICAL CASE)
|
№5 / 2016
|
|
E.V. Biryukova
EMPAGLIFLOZIN: ENHANCEMENT OF POTENTIALS OF THE TREATMENT OF TYPE 2 DIABETES MELLITUS
|
№5 / 2016
|
Русский
